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Abstract
Background: αB-crystallin is able to modulate vascular endothelial growth factor (VEGF) secretion. In many solid
tumors VEGF is associated with angiogenesis, metastasis formation and poor prognosis. We set out to assess
whether αB-crystallin expression is correlated with worse prognosis and whether this is related to VEGF secretion
and cell motility in head and neck squamous cell carcinoma (HNSCC).
Methods: αB-crystallin expression was determined immunohistochemically in tumor biopsies of 38 HNSCC patients.
Locoregional control (LRC) and metastasis-free survival (MFS) of the patients were analyzed in relation to
αB-crystallin expression. Additionally, the effects of αB-crystallin knockdown on VEGF secretion and cell motility
were studied in vitro.
Results: Patients with higher staining fractions of αB-crystallin exhibited a significantly shorter MFS (Log-Rank test,
p < 0.005). Under normoxic conditions αB-crystallin knockdown with two different siRNAs in a HNSCC cell line
reduced VEGF secretion 1.9-fold and 2.1-fold, respectively. Under hypoxic conditions, a similar reduction of VEGF
secretion was observed, 1.9-fold and 2.2-fold, respectively. The effect on cell motility was assessed by a gap closure
assay, which showed that αB-crystallin knockdown decreased the rate by which HNSCC cells were able to close a
gap by 1.5- to 2.0-fold.
Conclusions: Our data suggest that αB-crystallin expression is associated with distant metastases formation in
HNSCC patients. This association might relate to the chaperone function of αB-crystallin in mediating folding and
secretion of VEGF and stimulating cell migration.
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Background
The small heat shock protein αB-crystallin (HspB5) is
expressed in several types of cancer, including head and
neck squamous cell carcinomas (HNSCC) [1,2] and
breast carcinomas [3-5]. The expression is often corre-
lated with a poor prognosis, but the reason for this is
not fully understood [6,7]. αB-crystallin plays a role
in many different cellular processes such as prolifera-
tion, cell migration and apoptosis [3,6,8]. The expres-
sion of this protein is increased during various
stresses, like heat shock and oxidative stress [9]. A
well-known function of αB-crystallin is molecular
chaperoning, allowing the prevention of aggregation
of proteins [9]. Recently, it has been shown that αB-
crystallin chaperones the hypoxia-induced VEGF pro-
tein to the endoplasmic reticulum, leading to more
properly folded and thus secreted VEGF [10,11]. VEGF is
a major player involved in tumor angiogenesis [12] and
increased VEGF secretion is often correlated with
metastasis formation [13] and worse outcome for the
patient [14].
HNSCC is the sixth most common cancer worldwide
and accounts for 6% of all cancers [15]. The majority of
these patients are treated with radiotherapy, alone or in
combination with surgery or chemotherapy [16]. Based
on the improved understanding of the molecular path-
ways underlying HNSCC, targeted drugs (e.g. EGFR-
specific antibodies) and other modifications have been
implemented in treatment protocols [16]. However, only
a subset of patients profit from these combined modality
strategies. Therefore, there is a great demand for bio-
markers to customize treatment.
In the present study the value of αB-crystallin as a bio-
marker in HNSCC was investigated. αB-crystallin ex-
pression levels were immunohistochemically determined
in HNSCC biopsies and correlated with clinicopathologi-
cal characteristics and outcome. Moreover, the effect of




Biopsy material from a cohort of HNSCC patients with
stage II to IV primary squamous cell carcinoma of the
oral cavity, oropharynx, hypopharynx or larynx was used.
The inclusion criteria of patients with HNSCC have
been described before [17]. Approval from the ethics
committee of Radboud University Nijmegen Medical
Centre was obtained and all patients provided written
informed consent. Of 13 patients no biopsy materials
were left and were excluded from this study. The median
duration of follow-up for all patients was 29 months and
for surviving patients 85 months. During follow-up, LRC
and MFS were registered.
Immunohistochemical staining of αB-crystallin of HNSCC
biopsies
Oral cavity tumor sections [18] were incubated with 100-
fold diluted polyclonal rabbit αB-crystallin antiserum [19]
and subsequently stained with diaminobenzidine (DAB)
according to a standard protocol. Sections of the 38 avail-
able biopsies (5 μm) were mounted on poly-L-lysine
coated slides, fixed for 10 minutes in acetone at 4°C and
rehydrated in PBS. The sections were incubated overnight
at 4°C with 100-fold diluted αB-crystallin antiserum [19]
and subsequently incubated for 30 minutes at 37°C with
600-fold diluted goat-α-rabbit-FabCy3 (Jackson Immuno
Research Laboratories Inc) in PBS, for 45 minutes at 37°C
with 10-fold diluted endothelium antibody PAL-E (Euro
Diagnostica BV) in PAD, for 60 minutes at 37°C with
100-fold diluted chicken-α-mouse Alexa647 (Molecular
probes) in PBS and finally for 5 minutes at room
temperature with 0.5 ng/ml Hoechst (Sigma) in PBS. Be-
tween the incubation steps, 3 times 2 minutes washing
steps in PBS were performed. The sections were mounted
using fluorostab (ProGen Biotechnik GmbH).
Image acquisition
Scanning of the tumor sections was performed with a
fluorescence microscope (Axioskop, Zeiss) and a
computer-controlled motorized stepping stage, using IP-
lab software (Scanalytics)[20]. Each section was com-
pletely scanned for αB-crystallin staining. The resulting
grey scale images were subsequently binarized. Thresh-
olds were set just above the background staining for
each staining. Manually, the total tumor area was
contoured, excluding surrounding tissue, large necrotic
areas and artefacts. The percentage of αB-crystallin was
determined as the tumor area positive for αB-crystallin
relative to the total tumor area.
Cell culture, siRNA treatment, hypoxia exposure and VEGF
secretion measurement
The HNSCC cell line, UT-SCC-5 (described in [21]),
was maintained in DMEM + Glutamax™ (Invitrogen)
supplemented with 10% fetal calf serum (Gibco-BRL) in a
standard humidified 37°C incubator. At 40% confluency,
cells were transfected using Lipofectamine™ 2000 Reagent
according to the manufacturers’ protocol (Invitrogen). The
siRNAs used were si-Luciferase (siRNA LUC) as negative
control, sequence: CGUACGCGGAAUACUUCGAdTdT,
si-αB-crystallin1 (siRNA αB1) sequence: GCACCCAGC
UGGUUUGACAdTdT and si-αB-crystallin2 (siRNA αB2)
sequence: CCCUGAGUCCCUUCUACCUdTdT. After 5
hours, cells were reseeded (9.0x103 cells in 0.3 cm2 wells in
12-fold, for VEGF secretion measurements, and 2.5x105
cells in 10 cm2 wells in 4-fold, for RNA expression mea-
surements (see below)). Hypoxia treatment was performed
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24 hours after siRNA transfection cells in a humidified
37°C H35 Hypoxystation (Don Whitley Scientific) with
0.1% O2. Cells cultured under normoxic (6-fold) and hyp-
oxic (6-fold) conditions were maintained for 48 hours. The
culture media of the samples were collected and VEGF
levels were determined using a quantitative enzyme-linked
immunosorbent assay (ELISA). The details of this assay
have been described previously by Span and coworkers
[22]. The assay is based on the combination of four
polyclonal antibodies raised in four different animal
species, duck, chicken, rabbit and goat, and are
employed in a sandwich assay format. The assay mea-
sures VEGF165 and VEGF121, the main isoforms of
VEGF. There is no cross-reactivity with VEGF B, VEGF
C and VEGF D [22,23].
Gap closing assay
The HNSCC cell line UT-SCC-15 [21] was transfected
with siRNA as described above. Twenty-four hours after
transfection, cells were seeded at 1.0x105 cells per side of
the Culture-Inserts (Ibidi, N = 6 per condition). For quan-
titative RT-PCR, 0.5x106 cells were seeded in parallel in 10
cm2 wells (N = 5). 24 Hours later cells were washed with
PBS, fresh medium was added and the insert was re-
moved. Time lapse imaging was performed for 24 hours
in a microscope stage incubator (Oko-Lab) on a Nikon
DiaPhot microscope equipped with a Hamamatsu C8484-
05G digital camera. Images were taken every 10 min using
TimeLapse Software (Oko-Lab), version 2.7, with a 10x
objective. Analysis of gap closing was performed using
TScratch [24].
Figure 1 Immunohistochemical staining of tumor tissues with polyclonal anti-αB-crystallin antibody. DAB staining of three oral cavity
tumor sections. Tumor cells are indicated with T, surrounding stromal cells with S. (a). Immunofluorescent staining of biopsies with low
αB-crystallin expression (red, b left panel) and high αB-crystallin expression (red, c left panel) and the corresponding Hoechst stainings
(blue, b and c right panels). Blood vessels are indicated in white (b and c).
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RNA analysis by quantitative PCR
Total RNA from UT-SCC-5 and UT-SCC-15 cell lysates
was extracted using standard Trizol isolation. After DNAse
I treatment (Amplification grade, Invitrogen) mRNAs were
reverse transcribed using oligo(dT) primers and the Re-
verse Transcription System (Promega) according to manu-
facturer’s protocol starting with 1 μg of RNA in a total
volume of 20 μl. Subsequently quantitative PCR reactions
were performed with 10 μl Power SYBR Green (Applied
BioSystems), 5 μM of primers and 2 μl cDNA in a total
volume of 20 μl. The sequence of the used αB-crystallin
primers is: 50-ATCTTCTTTTGCGTCGCCAG-30 and
50-TTCCCCATGGTGTCTGAGC-30, and of the GAPD
H primers: 50-GATTGAGGTGCATGGAAAAC-30 and
50-AGGACCCCATCAGATGACAG-30. The fluorescent
signal intensities were recorded with the ABI Prism
7000 system (Applied Biosystems). Samples were kept
for 10 minutes at 95°C, followed by 40 cycles of 15 sec-
onds at 95°C and 1 minute at 60°C. Data analysis was
performed with 7000 System SDS software (Applied
BioSystems).
Statistics
Statistical analyses were performed using Graphpad
Prism 5.00 software. To test for differences in αB-crys-
tallin expression using binary patient data, the unpaired
t-test was used. For survival analyses, receiver operating
characteristic (ROC) curves were made to determine the
cut-off value with the highest sensitivity and specificity
for discriminating between patients with or without
locoregional recurrence (LRR) or distant metastasis with
at least 24 months of follow-up or an LRR or distant
metastatic event before that. Survival rates were calcu-
lated starting at the date of diagnosis. The Kaplan-Meier
method and the log-rank test were used to test for dif-
ferences in LRC and MFS rates in all patients. P-values
below 0.05 were considered a priori to indicate a signifi-
cant difference. Differences in VEGF secretion and gap
closure speed were tested using One-way ANOVA and
Tukey’s Multiple Comparison Test.
Results
The presence of αB-crystallin in the tumors was ana-
lyzed by immunohistological staining. In most tumors
cells αB-crystallin could be detected. In stromal cells, no
or only very low levels of nuclear staining were found
(Figure 1a). The αB-crystallin expression was determined
in 38 primary HNSCC biopsies, which were his-
tologically confirmed to contain tumor tissue [17].
The characteristics of the tumors at the time point
of biopsy collection are listed in Table 1. To quan-
tify the fraction of the tumor section expressing
αB-crystallin, fluorescently labeled secondary anti-
bodies were used and the images were analyzed with
a digital image analysis system. Only, the tumor area
was used for the analysis by excluding the surround-
ing stromal tissue, large necrotic areas and artifacts.
The results showed that the αB-crystallin expressing
tumor areas varied from 0 to 69%. Examples of bi-
opsies having marginal and extensive αB-crystallin
expression are shown in Figure 1b and c.
αB-crystallin expression in HNSCC biopsies is associated
with distant metastasis
Patients with at least 24 months of event-free follow up
or with a locoregional recurrence (LRR) or distant meta-
static event before 24 months were dichotomized in
groups with and without LRR (N = 16 and N = 12, re-
spectively), or with and without metastasis (N = 17 and
N = 10, respectively). Figure 2 shows that the mean per-
centage of the tumor area expressing αB-crystallin was
not significantly different between biopsies from patients
with or without LRR (Figure 2a). However, the mean
percentage of the tumor area expressing αB-crystallin
was significantly higher in biopsies from patients who
developed distant metastasis during follow up as com-
pared to those without (two-tailed unpaired t-test, p <
0.05, Figure 2b). The highest sensitivity and specificity
Table 1 Characteristics of 38 head and neck squamous
cell carcinomas
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for discriminating between patients with or without me-
tastasis was determined by receiver operating character-
istic (ROC) curve to be at a cut-off value of 20%. At this
cut-off value the Kaplan-Meier estimates for LRC did
not show any significant differences (Figure 2c), and the
same result was obtained with other cut-off values
(results not shown). For MFS a significant difference
was observed (Log-Rank, p < 0.005, Figure 2d), which
was especially clear after 22 months; at that time point
MFS was 86% for the patients with relatively low frac-
tions of tumor area expressing αB-crystallin, whereas
this was only 36% for the patients with extensive αB-
crystallin expression in the tumors. These results
suggest that the levels of αB-crystallin expression in-
versely correlate with MFS.
αB-crystallin expression enhances VEGF secretion
The recently reported involvement of αB-crystallin in
VEGF production prompted us to investigate the effects
of αB-crystallin expression on VEGF secretion by
HNSCC cells. For these experiments the HNSCC cell
line UT-SCC-5 was used and the levels of αB-crystallin
were reduced by siRNA-mediated knock-down. Two dis-
tinct αB-crystallin siRNAs, αB1 and αB2, resulted in a
1.3-fold and 1.8-fold reduction of αB-crystallin mRNA
levels, respectively (Figure 3a). Downregulation of αB-
Figure 2 Relation between αB-crystallin expression and locoregional recurrence and metastasis. αB-crystallin expression per biopsy and
the mean αB-crystallin expression of each group with standard error of the mean (SEM) in biopsies from patients without or with locoregional
recurrence (a) or metastasis (b) and Kaplan-Meier analysis of locoregional control (c) and metastasis-free survival (d) for patients with high
(>20% of tumor area) and low (<20% of tumor area) αB-crystallin expression. TA: Tumor area, ns: not significant.
Figure 3 Influence of αB-crystallin knock-down on VEGF secretion. Knockdown of αB-crystallin mRNA expression in UT-SCC-5 cells by two
different siRNAs, αB1 and αB2, compared to negative control siRNA LUC (Luciferase) as measured by quantitative PCR (a). VEGF secretion levels in
UT-SCC-5 cells transfected with the αB1, αB2 or LUC siRNA under normoxic and hypoxic conditions determined by ELISA (b). Statistical analysis
was performed using One-way ANOVA and Tukey’s Multiple Comparison Test. *** P < 0.001, ** 0.001 < P < 0.01, * 0.01 < P < 0.05; a.u:
absorbance units.
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crystallin significantly decreased VEGF secretion (1.9-
fold and 2.1-fold reduction, respectively). Since hypoxia
leads to elevated VEGF production, we next assessed the
effects of αB-crystallin knock-down under hypoxic
conditions. Indeed, VEGF secretion appeared to be
increased in UT-SCC-5 cells by hypoxia (Figure 3b, 1.6-
fold) and also under these conditions αB-crystallin de-
pletion resulted in decreased VEGF expression (1.9-fold
and 2.2-fold reduction, respectively). These results show
that αB-crystallin expression can affect VEGF secretion
both at normoxia and hypoxia.
Effect of αB-crystallin expression on cell migration
The association of αB-crystallin expression with metas-
tasis may also be due to effects on cell motility [3]. To
investigate whether motility of HNSCC cells is affected
by reduced αB-crystallin a gap closure assay was applied.
Since the UT-SCC-5 cells were easily damaged during
gap preparation, disturbing migration, the related cell
line UT-SCC-15 was used. Also in this HNSCC cell line
αB-crystallin mRNA levels could be diminished by
siRNA-mediated knock-down, although the efficiency
appeared to be much higher than that in the UT-SCC-5
cells (Figure 4a). Depletion of αB-crystallin resulted in
decreased gap closure rates compared to mock treated
cells (Figure 4b). The cell migration rate was reduced
2.0-fold from and 1.5-fold after treatment with the
siRNA αB1 and αB2, respectively (Figure 4c).
Discussion
Here, we show that αB-crystallin expression in HNSCC
tumors correlates with MFS, but not with LRC. Clues
for the mechanism by which αB-crystallin might affect
distant metastasis formation in patients were obtained
by the depletion of αB-crystallin in HNSCC cell lines,
which showed that both VEGF secretion and cell motil-
ity were decreased when αB-crystallin expression was
reduced.
Previously, two studies have addressed the prognostic
value of αB-crystallin in HNSCC. Chin and coworkers
have shown that αB-crystallin is a marker for poor prog-
nosis [1], which is substantiated by our data. However,
they noted that none of the patients lacking αB-crystallin
had LRR, while 37% of the patients with tumors stained
positive for αB-crystallin had LRR. In the current study,
the difference in prognosis was mainly caused by a
higher rate of distant metastasis in the high αB-crystallin
group and not by a difference in LRR. Boslooper and
colleagues did not find αB-crystallin to be a prognostic
marker for HNSCC [2]. These researchers observed the
highest concentrations of αB-crystallin in the centre of
tumor cell nests and not the more diffuse localization
observed in this study and the study of Chin and co-
workers [1]. This difference in αB-crystallin localization
may have been caused by a difference in staining proced-
ure and could be the reason why this study led to a dif-
ferent conclusion.
αB-crystallin was also found to be associated with a
poor prognosis in several other types of cancers, such as
breast cancer [3-5,25,26] and was downregulated in a
breast cancer cell line by breast cancer metastasis sup-
pressor 1, which specifically suppresses metastasis [27].
αB-crystallin is a molecular chaperone able to prevent
protein aggregation and can confer protection to cells
under stress conditions. αB-crystallin inhibits apoptosis
in response to different anti-cancer agents, such as
Figure 4 Influence of αB-crystallin knock-down on cell
migration determined with gap closure assay. Knockdown of αB-
crystallin mRNA expression in UT-SCC-15 cells by two different
siRNAs, αB1 and αB2, compared to negative control siRNA LUC
(Luciferase) as measured by quantitative PCR (a). Representative
micrographs of the gap closure by UT-SCC-15 cells after 0 and 180
minutes at 10x magnification. (b). Relative gap size between 0 and
180 minutes of UT-SCC-15 cells transfected with the αB1, αB2 or
LUC siRNA (c). Statistical analysis was performed using One-way
ANOVA and Tukey’s Multiple Comparison Test. *** P < 0.001,
* 0.01 < P < 0.05.
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DNA-damaging drugs, TNFα and Fas ligand [6] and has
been shown to be a predictor of resistance to chemo-
therapy [28]. However, since our data do not support an
association of αB-crystallin expression with local recur-
rence after treatment of the patients, the cytoprotective
activity is likely not the sole reason why αB-crystallin is
associated with poor prognosis.
Metastasis formation occurs via a series of steps,
also known as the “metastatic cascade” [29]. One of
the factors associated with metastatic spread is VEGF
[30,31]. Several studies have demonstrated roles for
αB-crystallin in VEGF-dependent angiogenesis [32].
Tumor vasculature in αB-crystallin-deficient mice dis-
plays high levels of endothelial apoptosis and de-
creased vessel formation. αB-crystallin has been shown
to associate with VEGF-A (the most well-known mem-
ber of the VEGF protein family) [8,33] and colocalizes
with VEGF at the endoplasmic reticulum [11]. Further-
more, VEGF-A expression remained low in αB-crystallin-
deficient mice during retinal revascularization after
artificially-induced retinopathy [10]. Here we have
shown that in a HNSCC cell line αB-crystallin is also
involved in secretion of VEGF and in this way may in-
fluence tumorigenic blood vessel formation and metas-
tasis formation in HNSCC. For the growth of metastatic
tumors in lymph nodes neoangiogenesis is not abso-
lutely needed [34,35], which might explain why no cor-
relation was found between αB-crystallin expression
and LRC.
Migration-associated proteins may also correlate with
worse outcome, as has been shown for patients with squa-
mous cell carcinoma of the tongue [36]. αB-crystallin can
affect cell migration as well. Overexpression of αB-crystal-
lin led to higher cell motility in several studies [3,25,37].
Here we have shown that depletion of αB-crystallin de-
creased the motility of UT-SCC cells, indicating also in
these types of cells αB-crystallin may affect cell migration.
VEGF also plays a role in cell migration [38], potentially
by enhancing invadopodia formation [39]. The effect of
αB-crystallin on cell migration may thus be mediated by
VEGF, although other mechanisms are also possible, as for
example by the influence of αB-crystallin on actin fila-
ments dynamics [39,40]. Further research is needed to re-
veal the molecular mechanisms by which αB-crystallin
affects cell migration.
Conclusions
High αB-crystallin expression is associated with metastasis
formation in HNSCC but not with locoregional recurrence.
αB-crystallin could be a useful biomarker to help fine-tune
treatment, possibly by targeting αB-crystallin-induced
VEGF secretion or cell motility. Validation in a larger
HNSCC cohort is required to confirm the significance of
this finding.
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